Glenmark Pharmaceuticals Ltd. sees a credit rating action

Verdict: India Ratings’ announcement confirms Glenmark’s upgrade from IND AA to IND AA+, but the retrieved AA+ notice does not state the specific before-and-after Net Debt/EBITDA or interest-coverage figures behind the action. ^[1] The only detailed India Ratings rationale available is for the earlier April 2024 upgrade to IND AA, so its figures should not be presented as the numerical basis for the AA+ upgrade. ^[2]

What India Ratings previously disclosed

For the April 2024 action, India Ratings cited:

• Consolidated net adjusted leverage: around 1.4x in FY23, versus 1.1x in FY22; it expected leverage to turn negative in FY24 and remain negative over the following two to three years, following repayment of Glenmark’s long-term debt, apart from a USD 19 million ECB. ^[2]
• Interest coverage: 6.5x in FY23, versus 7.8x in FY22. Thus, the historical FY23 coverage figure was actually lower; the rating rationale relied more on prospective deleveraging and expected credit-metric improvement than on a year-on-year increase in coverage. ^[2]

Alignment with the latest reported consolidated figures

Analyst read:

• The latest quarter remains consistent with a very strong leverage profile: Net Debt/EBITDA was negative at -1.35x, while consolidated net debt was negative Rs 1,174.7 Crores and total debt was Rs 0.00 Crores. ^{[7] [8]}
• Interest coverage of 16.12x in Q1 FY27 is well above the 6.5x reported in the earlier India Ratings rationale, although the definitions and periods may not be identical. ^{[5] [2]}
• The direction is mixed on a quarter-on-quarter basis: leverage became marginally more negative, but quarterly interest coverage declined from 22.34x to 16.12x. On a TTM basis, however, coverage improved from 10.51x to 13.38x, while TTM Net Debt/EBITDA stayed negative at approximately -0.22x. ^{[4] [6]}

Bottom line: Glenmark’s latest reported metrics strongly support the broad credit-quality narrative of net cash and ample interest-servicing capacity. However, the precise numerical improvement that India Ratings cited for the IND AA+ upgrade is not disclosed in the retrieved AA+ announcement; the detailed 1.4x-to-negative leverage trajectory belongs to the earlier IND AA action.

Glenmark’s post-upgrade facility mix is Rs 4,200 Crores of rated bank limits, with Rs 1,850 Crores in the upgraded long-term facility and Rs 2,350 Crores in additional facilities. That equates to approximately 44% long-term and 56% additional/other facilities, derived from the rated limits reported by India Ratings. ^[1]

† Derived from the reported Rs 1,850 Crores and Rs 2,350 Crores limits.

The bank-wise facility disclosure provides a second view of the same rated limits: Rs 2,200 Crores of fund-based working-capital limits and Rs 2,000 Crores of non-fund-based limits. ^[1] These are rated limits, not necessarily drawn debt. In fact, Glenmark’s latest consolidated KPI data shows total debt of zero for Q1 FY27. ^[8]

Weighted average cost of debt: a numeric management target for the expected reduction in weighted average cost of debt—whether in basis points or percentage terms—is not reported in the cited rating announcement or earnings material. The rating upgrade may affect future borrowing economics, but the available evidence does not support attributing a specific reduction to management.

Glenmark’s IND AA+/Stable is not directly rankable against most named peers because the disclosed peer ratings are not on the same basis. However, on the underlying balance sheet, Glenmark is materially stronger than the closest-scale peers, Biocon and Alkem, because it reported zero total debt and net cash at the latest period. ^[9]

Glenmark

• Scale and leverage: Q1 FY27 TTM revenue was Rs 17,736.5 Crores; reported total debt was zero and net debt was negative Rs 1,174.7 Crores, implying net cash. ^{[10] [8] [7]}
• Rating: India Ratings upgraded Glenmark’s long-term bank-loan rating to IND AA+/Stable from IND AA and affirmed the short-term rating at IND A1+. This is a bank-loan rating, not an issuer rating. ^[9]
• Credit interpretation: The combination of net cash, zero reported gross debt and strong FY26 adjusted interest coverage of 21.9x supports a stronger credit profile than the two closest revenue-scale peers. ^[11]

Biocon

• Scale and leverage: Q1 FY27 TTM revenue was Rs 17,321.1 Crores, close to Glenmark’s scale. However, total debt was Rs 14,824.7 Crores and net debt was Rs 12,408.2 Crores. ^{[12] [13] [14]}
• Rating evidence: The cited rating item concerns Biocon Biologics, not Biocon Ltd, and refers to an S&P Global BB+ rating. It is therefore not a like-for-like comparison with Glenmark’s domestic IND AA+ bank-loan rating. ^[15]
• Credit interpretation: Biocon’s substantially higher leverage makes its balance-sheet credit profile weaker than Glenmark’s despite similar revenue scale.

Alkem

• Scale and leverage: Q1 FY27 TTM revenue was Rs 15,081.3 Crores. Total debt was Rs 1,623.5 Crores and net debt was Rs 1,375.6 Crores. ^{[16] [17] [18]}
• Rating evidence: India Ratings affirmed Alkem’s commercial paper at IND A1+. That is a short-term rating and cannot be directly compared with Glenmark’s long-term IND AA+. ^[19]
• Credit interpretation: Alkem has a sounder leverage position than Biocon but remains meaningfully more indebted than Glenmark on the latest reported numbers.

Ipca Laboratories

• Scale and leverage: Q1 FY27 TTM revenue was Rs 10,125.6 Crores, with total debt of Rs 703.9 Crores and net debt of Rs 266.8 Crores. ^{[20] [21] [22]}
• Rating evidence: A comparable current domestic long-term rating was not reported in the cited material.
• Credit interpretation: Ipca is smaller than Glenmark and carries modest net debt; its credit profile cannot be ranked against AA+ without a comparable rating disclosure.

Abbott India

• Scale and leverage: Abbott India’s Q4 FY26 TTM revenue was Rs 6,929.1 Crores on a standalone basis. It reported zero total debt and net cash of Rs 442.3 Crores. ^{[23] [24] [25]}
• Rating evidence: A comparable current domestic long-term rating was not reported in the cited material.
• Credit interpretation: Abbott India is much smaller and debt-free, but its standalone basis and absence of a comparable rating limit a direct comparison with Glenmark’s consolidated bank-loan rating.

Gland Pharma

• Scale and leverage: Q1 FY27 TTM revenue was Rs 6,725.3 Crores. Total debt was Rs 243.4 Crores and net cash was Rs 3,115.8 Crores. ^{[26] [27] [28]}
• Rating evidence: A comparable current domestic long-term rating was not reported in the cited material.
• Credit interpretation: Gland has an even larger net-cash buffer relative to its revenue, but it operates at a materially smaller revenue scale and cannot be assigned a rating position relative to Glenmark from the disclosed information.

Does the upgrade reflect a material liquidity change?

Yes, but the change is primarily in cash generation and debt-service risk—not in the absolute cash balance.

• Glenmark’s cash balance actually declined from Rs 1,680 Crores at FYE25 to Rs 1,180 Crores at FYE26, approximately a 30% reduction. ^[29]
• The more important change was the cash-flow inflection: operating cash flow turned positive at Rs 3,280 Crores in FY26 versus negative Rs 980 Crores in FY25, while free cash flow turned positive at Rs 1,780 Crores versus negative Rs 1,800 Crores. ^[29]
• Glenmark also had no scheduled debt repayments in FY27 or FY28 and no outstanding short- or long-term debt at FYE26. ^[29]
• Ind-Ra attributed the improvement mainly to the ISB 2001 licensing transaction: Glenmark recognised USD 560 million in FY26, which reduced the need for the subsidiary IGI to rely on parent funding and helped produce negative net adjusted leverage of 0.13x, versus positive 0.34x in FY25. ^[11]

The qualification is that FY26 cash generation was heavily influenced by the licensing transaction and therefore is not entirely representative of recurring pharmaceutical operating cash flow. Working-capital intensity also worsened, with the net working-capital cycle increasing to 100 days from 91 days. ^[29] Accordingly, the upgrade reflects a material improvement in liquidity resilience and leverage, but the durability of the stronger credit profile will depend on recurring cash generation after the licensing-related benefit normalises.